Cognetivity Neurosciences Ltd. announced the appointment of Ms. Karimah Es Sabar as a Board Director. Ms. Es Sabar is a highly-recognized life sciences leader with broad international experience, spanning the global biopharmaceutical industry, start-ups, not-for-profit organizations, and venture investment. She is currently the Chief Executive Officer and General Partner at Quark Venture LP and Chair of the Health Bioscience Economic Strategy Table for the Government of Canada.

Throughout her distinguished career, Ms. Es Sabar has demonstrated her ability to nurture and build high impact teams and organizations, with a focus on international marketing, business development, strategic alliances, public-private partnerships, and health technology venture capital investments. She has raised over $1.5 billion for various private and public global biosciences enterprises. In her previous roles, Ms. Es Sabar has led The Centre for Drug Research and Development as President &CEO, re-engineered and rebranded BC Biotech into LifeSciences BC, and held senior management positions with multinational pharmaceutical companies such as Sanofi Pasteur.

She has also served as Vice President and COO for Medsurge Medical Inc., founded two start-up companies, and served on numerous corporate boards. Ms. Es Sabar holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management, a MSc degree in Neurochemistry from the Institute of Psychiatry, University of London, England, and a BSc Joint Honors degree in Biochemistry/Chemistry from the University of Salford, Manchester, England.